The High Cost of Innovation: Why Australia’s PBS System Fails Patients and Progress
The recent standoff between Eli Lilly and the Australian government over the diabetes drug Mounjaro isn’t just a corporate spat—it’s a symptom of a deeper systemic issue. Personally, I think this case exposes the fragility of a healthcare system that claims to prioritize affordability but struggles to keep pace with medical innovation. What makes this particularly fascinating is how it highlights the tension between patient access, corporate profit, and public funding. Let’s break it down.
The PBS: A Lifeline with Limitations
Australia’s Pharmaceutical Benefits Scheme (PBS) is often hailed as a model for making essential medications affordable. For just $25 (or $7.70 for concession card holders), patients can access life-saving drugs. But here’s the catch: the path to PBS listing is a bureaucratic labyrinth. From my perspective, the 22-month median wait time for new medicines to be listed is more than just an inconvenience—it’s a moral failure. Patients like Ingrid Baas-Becking, a 74-year-old double diabetic, are forced to ration their medication or go without, simply because the system can’t keep up.
What many people don’t realize is that the PBS isn’t just slow; it’s also increasingly out of touch with the pace of medical innovation. Medicines Australia CEO Liz de Somer calls the system “broken,” and I couldn’t agree more. The Mounjaro debacle is just the latest example of how the PBS’s rigid processes undervalue cutting-edge treatments. Eli Lilly walked away from negotiations because Australia’s proposed price for Mounjaro was, in their words, “unrealistic and unviable.” But is this just corporate greed, or a legitimate critique of a system that fails to recognize the value of innovation?
The Human Cost of Bureaucracy
Ingrid Baas-Becking’s story is heartbreaking. She’s losing weight and using 50% less insulin thanks to Mounjaro, but she’s forced to halve her dose to make it affordable. This isn’t just a financial burden—it’s a health risk. If you take a step back and think about it, the PBS is supposed to protect patients, not force them into impossible choices. Yet, here we are, with hundreds of thousands of Australians missing out on a drug that could transform their lives.
One thing that immediately stands out is the disconnect between the PBS’s goals and its execution. The system is designed to protect taxpayers by keeping costs low, but at what expense? Health economist Philip Clarke points out that every dollar spent on one drug means less funding for others. It’s a zero-sum game, and patients like Ingrid are the ones losing. This raises a deeper question: Is the PBS’s commitment to affordability actually undermining its ability to deliver the best care?
The Global Implications of a Local Crisis
This isn’t just an Australian problem. The tensions between governments and pharmaceutical companies over drug pricing are playing out worldwide. What this really suggests is that the current model for funding innovation is broken. US pharma companies have long criticized the PBS for undervaluing their products, and the Mounjaro case is just the latest flashpoint. But here’s the irony: by refusing to list Mounjaro, Australia isn’t just failing its own citizens—it’s also sending a signal to innovators that their work may not be rewarded.
A detail that I find especially interesting is the role of alternatives like Ozempic and Wegovy, which are already on the PBS. Critics might argue that Mounjaro isn’t essential because there are other options. But innovation isn’t about replacing what works—it’s about creating something better. Mounjaro’s dual-hormone approach is unique, and for patients like Ingrid, it’s a game-changer. By refusing to list it, the PBS isn’t just saving money; it’s limiting progress.
The Way Forward: Urgency Over Incrementalism
The 2024 Health Technology Assessment (HTA) review offered a roadmap for reform, but progress has been glacial. Medicines Australia is right to demand urgent action, but will the government listen? Health Minister Mark Butler’s response—that robust negotiations are necessary to keep the PBS sustainable—feels like a cop-out. Yes, sustainability matters, but so does innovation. What we need is a system that balances both, not one that sacrifices one for the other.
In my opinion, the PBS needs a fundamental rethink. It’s not just about streamlining processes or tweaking prices; it’s about reimagining how we value medical innovation. If we continue down this path, we risk becoming a country that talks about progress but refuses to pay for it. And that’s a future no patient deserves.
Final Thoughts
The Mounjaro saga isn’t just a story about a drug—it’s a story about priorities. Do we value innovation enough to pay for it? Are we willing to rethink a system that’s failing patients? Personally, I think the answers to these questions will define not just Australia’s healthcare future, but its place in the global innovation landscape. The time for incremental change is over. What’s needed now is bold, visionary reform. Anything less is a disservice to patients like Ingrid—and to the promise of progress itself.
